1 / 31

Stribild ™ - Elvitegravir/cobicistat/emtricitabine/tenofovir

Stribild ™ - Elvitegravir/cobicistat/emtricitabine/tenofovir. Manufacturer: Gilead Sciences FDA Approval Date: August 2012. Stribild ™ - Elvitegravir/cobicistat/emtricitabine/tenofovir Clinical Application. Indications:

baka
Download Presentation

Stribild ™ - Elvitegravir/cobicistat/emtricitabine/tenofovir

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Stribild™ - Elvitegravir/cobicistat/emtricitabine/tenofovir Manufacturer: Gilead Sciences FDA Approval Date: August 2012

  2. Stribild™ - Elvitegravir/cobicistat/emtricitabine/tenofovirClinical Application • Indications: • Complete regimen for the treatment of HIV-1 infection in adults who are antiretroviral treatment-naïve • Place in therapy: • First line therapy - option

  3. Stribild™ - Elvitegravir/cobicistat/emtricitabine/tenofovirClinical Application • Contraindications: • Coadministration with drugs highly dependent on CYP3A for clearance & for which elevated concentrations may lead to serious or life threatening events (e.g. alfuzosin, rifampin, ergotamines, cisapride, St. John’s wort, lovastatin, simvastatin, pimozie, sildenafil (Revatio), triazolam, PO midazolam)

  4. Stribild™ - Elvitegravir/cobicistat/emtricitabine/tenofovirClinical Application • Black Box warnings • Lactic acidosis/severe hepatomegaly • Reports, including fatalities, have been reported for the use of nuceloside analogs in combination with other antiretrovirals • Hepatitis B coinfection • Safety and efficacy not studied. Reports of severe, acute exacerbations of hepatitis B have been reported in coinfected patients who discontinued emtricitabine or tenofovir. Monitor renal function for several months in coinfected patients who discontinue this drug. Consider initiating anti-hepatitis B treatment.

  5. Stribild™ - Elvitegravir/cobicistat/emtricitabine/tenofovirClinical Application • Warnings and Precautions • New onset or worsening renal impairment • Use with other antiretroviral products – Stribild™ is a complete regimen • Decreases in bone mineral density • Fat redistribution • Immune reconstitution syndrome

  6. Stribild™ - Elvitegravir/cobicistat/emtricitabine/tenofovirClinical Application • Pregnancy: • Category B • Lactation: • CDC recommends for HIV infected mothers not to breastfeed their infants to avoid postnatal transmission of HIV

  7. Stribild™ - Elvitegravir/cobicistat/emtricitabine/tenofovirDrug Facts • Pharmacology • Emtricitabine – nucleoside reverse transcriptase inhibitor • nucleoside analog of cytidine; once phosphorylated to emtricitabine-5’TP, it competes with the natural substrate and inhibits the activity of HIV-1 reverse transcriptase resulting in chain termination • Tenofovir disoproxil fumarate - nucleoside analog HIV-1 reverse transcriptase • acyclic nucleoside analog of AMP; after hydrolysis and phosphorylation to form tenofovir diphosphate, it can now inhibit the HIV-1 reverse transcriptase by competing with the natural substrate to be incorporated into the DNA

  8. Stribild™ - Elvitegravir/cobicistat/emtricitabine/tenofovirDrug Facts • Pharmacology • Elvitegravir - an integrase strand transfer inhibitor • works on HIV-1 integrase to inhibit its strand transferring activity and as a result, preventing the HIV-1 DNA from integrating into the host DNA • Cobicistat - selective inhibitor of CYP450 3A family • works to increase the systemic exposure of CYP3A substrate, elvitegravir

  9. Stribild™ - Elvitegravir/cobicistat/emtricitabine/tenofovirDrug Facts • Pharmacokinetics • A – light meal (20% fat)  elvitegravir (34%) & tenofovir (24%); high fat meal (50% fat)  elvitegravir (87%) & tenofovir (23%) • D – protein binding: elvitegravir 98-99%; cobicistat 97-98%; emtricitabine <4%; tenofovir <0.7% • M – elvitegravir (CYP3A, glucoronidation); cobicistat (CYP3A, CYP2D6); emtricitabine and tenofovir not significantly metabolized • E – elvitegravir t1/2 9h (urine, feces); cobicistat t1/2 3.5 h (urine, feces); emtricitabine & tenefovir (urine)

  10. Stribild™ - Elvitegravir/cobicistat/emtricitabine/tenofovirDrug Interactions • Drug Interactions – Object Drugs • Antiarrhythmics, digoxin (serum concentration) • Clarithromycin, telithromycin (serum concentration) • Clonazepam, ethosuximide (serum concentration) • SSRIs, TCAs, trazodone (serum concentration) • Ketoconazole, itraconazole, voriconazole (serum concentration) • Colchicine  (do not coadminister in pts with renal/hepatic impairment) • Beta blockers, calcium channel blockers (serum concentration) • Salmeterol, fluticasone (serum concentration) • Bosentan (serum concentration) • Atorvastatin (serum concentration) • Norgestimate ; ethinyl estradiol  (use alternative contraceptive) • Cyclosporine, sirolimus, tacrolimus (serum concentration) • Perphenazine, risperidone, thioridazine (serum concentration) • PDE5 inhibitors (hypotension, syncope, visual disturbances, priapism) • BZDs (serum concentration)

  11. Stribild™ - Elvitegravir/cobicistat/emtricitabine/tenofovirDrug Interactions • Drug Interactions – Precipitant Drugs • Antacids elvitegravir (separate by at least 2h) • Clarithromycin, telithromycin cobicistat • Carbamazepine, oxcarbazepine, phenobarbital, phenytoin  cobicistat, elvitegravir (use alternative anticonvulsant) • Rifabutin, rifapentine elvitegravir, cobicistat (avoid coadministration) • Dexamethasone  elvitegravir, cobicistat

  12. Stribild™ - Elvitegravir/cobicistat/emtricitabine/tenofovirAdverse Effects

  13. Stribild™ - Elvitegravir/cobicistat/emtricitabine/tenofovirAdverse Effects

  14. Stribild™ - Elvitegravir/cobicistat/emtricitabine/tenofovirMonitoring Parameters • Efficacy Monitoring • HIV RNA, CD4 count • Toxicity Monitoring • Renal function • Liver function tests • HBV coinfection

  15. Stribild™ - Elvitegravir/cobicistat/emtricitabine/tenofovirPrescription Information • Dosing – Initial and Maintenance • 1 tablet PO daily with food • Dosing – Max • Unknown • Cost – accessed 01/02/2013 • $2451 (www.goodrx.com)

  16. Stribild™ - Elvitegravir/cobicistat/emtricitabine/tenofovirLiterature Review: Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks Sax PE, et al. Lancet. 2012;379:2439-2448.

  17. Stribild™ - Elvitegravir/cobicistat/emtricitabine/tenofovirLiterature Review: Sax PE, et al. Lancet. 2012;379:2439-2448.

  18. Stribild™ - Elvitegravir/cobicistat/emtricitabine/tenofovirLiterature Review: • Inclusion Criteria: • Infected with HIV-1 • >18 years old • HIV-1 RNA > 5000 copies/mL • No previous use of antiretroviral drugs • GFR >70 mL/min • Susceptible to efavirenz, emtricitabine, tenofovir • AST/ALT<5x ULN, Tbili <25.65 umol/L, ANC>1000 cells/uL, plts>50,000/uL; Hgb>85 g/L; negative pregnancy test Sax PE, et al. Lancet. 2012;379:2439-2448.

  19. Stribild™ - Elvitegravir/cobicistat/emtricitabine/tenofovirLiterature Review: • Exclusion Criteria: • Patients with new AIDS-defining disorders or serious infections within 30 days of screening were excluded Sax PE, et al. Lancet. 2012;379:2439-2448.

  20. Stribild™ - Elvitegravir/cobicistat/emtricitabine/tenofovirLiterature Review: • Intervention (1:1) • Elvitegravir 150 mg/cobicistat 150 mg/ emtricitabine 200 mg/tenofovir 300 mg once daily with food • Efavirenz 600 mg/emtricitabine 200 mg/tenofovir 300 mg QHS on empty stomach Sax PE, et al. Lancet. 2012;379:2439-2448.

  21. Stribild™ - Elvitegravir/cobicistat/emtricitabine/tenofovirLiterature Review: • Primary endpoint: • Proportion of patients in the intention-to-treat population with viral suppression (HIV RNA <50 copies/mL) at week 48 Sax PE, et al. Lancet. 2012;379:2439-2448.

  22. Stribild™ - Elvitegravir/cobicistat/emtricitabine/tenofovirLiterature Review: • Other endpoints: • Treatment differences by subgroup • Achievement and maintenance of HIV RNA <50 copies/mL • Proportion of patients with HIV RNA <50 copies/mL when classing missing as failure and missing as excluded • Change in HIV RNA concentration and CD4 count from baseline Sax PE, et al. Lancet. 2012;379:2439-2448.

  23. Stribild™ - Elvitegravir/cobicistat/emtricitabine/tenofovirLiterature Review: Results • Primary endpoint: • EVG/COBI/FTC/TDF 87.6% versus EFV/FTC/TDF 84.1% • Difference 3.6%, 95% CI (-1.6 to 8.8%) • Non-inferior Sax PE, et al. Lancet. 2012;379:2439-2448.

  24. Stribild™ - Elvitegravir/cobicistat/emtricitabine/tenofovirLiterature Review: Results Sax PE, et al. Lancet. 2012;379:2439-2448.

  25. Stribild™ - Elvitegravir/cobicistat/emtricitabine/tenofovirLiterature Review: Results Sax PE, et al. Lancet. 2012;379:2439-2448.

  26. Stribild™ - Elvitegravir/cobicistat/emtricitabine/tenofovirLiterature Review: Results Sax PE, et al. Lancet. 2012;379:2439-2448.

  27. Stribild™ - Elvitegravir/cobicistat/emtricitabine/tenofovirLiterature Review: AE Sax PE, et al. Lancet. 2012;379:2439-2448.

  28. Stribild™ - Elvitegravir/cobicistat/emtricitabine/tenofovirLiterature Review: AE Sax PE, et al. Lancet. 2012;379:2439-2448.

  29. Stribild™ - Elvitegravir/cobicistat/emtricitabine/tenofovirLiterature Review: Conclusion • EVG/COBI/FTC/TDF was non-inferior to EFV/FTC/TDF (standard of care) for HIV-1 infection in treatment naïve patients. • Nausea and increased serum creatinine were more common in EVG/COBI/FTC/TDF group, but dizziness, abnormal dreams, insomnia, and rash were less common when compared to EFV/FTC/TDF. • EVG/COBI/FTC/TDF is the first single-tablet, once-daily, integrase-inhibitor based regimen for HIV infection in treatment naïve patients. Sax PE, et al. Lancet. 2012;379:2439-2448.

  30. Stribild™ - Elvitegravir/cobicistat/emtricitabine/tenofovirSummary • Stribild™ is a complete, fixed-combination, once daily, integrase-inhibitor based regimen for HIV-1 infected patients who are naïve to treatment. • Stribild™ is composed of 150 mg elvitegravir, 150 mg cobicistat, 200 mg emtricitabine, and 300 mg tenofovir. • Precautions include declining renal function or bone mineral density, fat redistribution, immune reconstitution syndrome, HBV coinfections, and lactic acidosis/severe hepatomegaly. • Elvitegravir and cobicistat, the novel components of Stribild™, work as an integrase inhibitor and as a pharmacokinetic enhancer, respectively.

  31. Stribild™ - Elvitegravir/cobicistat/emtricitabine/tenofovirReferences • http://www.Stribild.com • Stribild package insert. Foster City, CA. Gilead Sciences. January 2013. • Sax PE, et al. Co-formulated elvitegarivr, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomized, double-blind, phase 3 trial, analysis of results after 48 weeks. Lancet. 2012;379:2439-48.

More Related